Pharmacokinetics Study of Dipeptidyl Peptidase 4 Inhibitor to Control Type 2 Diabetes Mellitus
Mechanism of Reduced Response to DPP-4 Inhibitor in Patients With Type 2 Diabetes Mellitus
研究概览
详细说明
Sitagliptin, a DPP-4 inhibitor was used as an incretin enhancer in clinical practice first. In clinical trials, sitagliptin showed effective control of blood glucose level in type 2 diabetes and 100 mg once daily with metformin was similar to sulfonylurea (glipizide) with metformin in lowering HbA1c. Mostly in practice, stable blood glucose levels were maintained after change of sulfonylurea to sitagliptin in type 2 diabetes treatment. However, in some cases, there were abrupt severe hyperglycemia and uncontrolled blood glucose level after drug change to sitagliptin.
Several mechanism could be considered for reduced response to DPP-4 inhibitor in some type 2 diabetes patients. Firstly, significantly reduced secretion of glucagon-like peptide 1 (GLP-1) more than expected in diabetes or functional defect of GLP-1 activity could be the mechanism of loss of GLP-1 effect irrespective of DPP-4. Secondly, mutation or functional defect of DPP-4 enzyme could not be inhibited by DPP-4 inhibitor. Thirdly, GLP-1 receptor mutation or other defect in β-cell responsiveness to GLP-1 leads to reduction of response to DPP-4 inhibitor.
研究类型
注册 (实际的)
阶段
- 第四阶段
联系人和位置
学习地点
-
-
-
Seoul、大韩民国、130-709
- The Catholic University of Korea; St.Paul's Hospital
-
Seoul、大韩民国、137-701
- The Catholic University of Korea; Seoul St. Mary's Hospital
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Type 2 diabetic patients with less than 15 yrs of disease duration
- BMI between 22-27 kg/m2
HbA1c ≤ 9% at recruitment
- Study group
After change sulfonylurea to sitagliptin in case of metformin and sulfonylurea therapy
- Increase of fasting blood glucose over 20 mg/dL or postprandial glucose over 30 mg/dL within several days or
Increase of HbA1c over 1% within 2-3 months without abrupt increase of blood glucose levels within several days
- Sulfonylurea dose : less than glimepiride 4mg or gliclazide 120mg or glibenclamide 10mg
- Metformin dose : 500~2000mg
- Reduced response to sitagliptin should be made a decision by investigators after understanding the condition of patients surely.
2. Control group
- Age, sex, BMI matched patients with same condition of study patients
- After change sulfonylurea to sitagliptin in case of metformin plus sulfonylurea therapy, no change of blood glucose levels like above or stable HbA1c change within 1% within 2-3 months
Exclusion Criteria:
- Other causes of increase of blood glucose levels except drug change
- Patients with history of insulin treatment
- Patients taking thiazolidinediones, alpha-glucosidase inhibitors, GLP-1 analogue or DPP-4 inhibitors
- Patients with renal, hepatic dysfunction
- Patients with diabetic complications such as coronary heart disease, cerebrovascular disease, proliferative diabetic retinopathy or diabetic gastroparesis
- Patients taking medications affecting glucose level
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
有源比较器:study group
sitagliptin hypo-response patients
|
Sitagliptin (100mg, per oral) once a day.
其他名称:
|
假比较器:control group
sitagliptin response patients
|
Sitagliptin (100mg, per oral) once a day.
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Plasma Concentration of Active Glucagon-like Peptide 1 (GLP-1) Before and After Sitagliptin Treatment
大体时间:0, 15, 30, 45, 60, 90, 120, 180 min pre and post-dose
|
Plasma concentrations of active GLP-1 were measured at 0, 15, 30, 45, 60, 90, 120 and 180 min during the meal tolerance test (MTT).
Second measurement of active GLP-1 were measured with MTT after taking sitagliptin 100 mg 1 hour before the test.
|
0, 15, 30, 45, 60, 90, 120, 180 min pre and post-dose
|
Plasma Concentration of Total GLP-1 Before and After Sitagliptin Treatment
大体时间:0, 15, 30, 45, 60, 90, 120, 180 min pre and post-dose
|
Plasma concentrations of total GLP-1 were measured at 0, 15, 30, 45, 60, 90, 120 and 180 min during the meal tolerance test.
Second measurement of total GLP-1 were measured with MTT after taking sitagliptin 100 mg 1 hour before the test.
|
0, 15, 30, 45, 60, 90, 120, 180 min pre and post-dose
|
Plasma Concentration of Total Glucose-dependent Insulinotropic Polypeptide (GIP) Before and After Sitagliptin Treatment
大体时间:0, 15, 30, 45, 60, 90, 120, 180 min pre and post-dose
|
Plasma concentrations of total GIP were measured at 0, 15, 30, 45, 60, 90, 120 and 180 min during the meal tolerance test.
Second measurement of total GIP were measured with MTT after taking sitagliptin 100 mg 1 hour before the test.
|
0, 15, 30, 45, 60, 90, 120, 180 min pre and post-dose
|
Change in AUC of Active GLP-1, Total GLP-1 and Total GIP Between Before and After Sitagliptin Treatment
大体时间:0, 15, 30, 45, 60, 90, 120, 180 min pre and post-dose
|
Plasma concentrations of active GLP-1, total GLP-1 and total GIP were measured at 0, 15, 30, 45, 60, 90, 120 and 180 min during the meal tolerance test.
Second measurements were measured with MTT after taking sitagliptin 100 mg 1 hour before the test.
Comparisons were made using Area under the curve (AUC) values and incremental area under the curve (ΔAUC) of active GLP-1, total GLP-1 and total GIP before and after the addition of sitagliptin.
|
0, 15, 30, 45, 60, 90, 120, 180 min pre and post-dose
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Differences of DPP-4 Activity After Sitagliptin Treatment Between Responder and Non-responder Groups
大体时间:0, 15, 30, 45, 60 min post-dose
|
The DPP-4 activity was measured at baseline and 0, 15, 30, 45 and 60 min during the meal tolerance test.
Second measurement of DPP-4 activity was measured with MTT after taking sitagliptin 100 mg 1 hour before the test.
Plasma DPP-4 activity during meal tolerance test is expressed as percentage activity relative to baseline.
DPP-4 activity % was calculated using the following formula : (DPP-4 activity at time t / Baseline DPP-4 activity) × 100.
|
0, 15, 30, 45, 60 min post-dose
|
合作者和调查者
调查人员
- 首席研究员:Ji Hyun Kim, Dr、The Catholic University of Korea
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.